Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a report released on Thursday morning,Benzinga reports. The brokerage currently has a $4.00 price objective on the stock.

A number of other equities research analysts have also weighed in on the company. Benchmark reiterated a “speculative buy” rating and issued a $3.00 price objective on shares of Hoth Therapeutics in a research report on Friday, October 11th. D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a research note on Tuesday, January 7th.

Hoth Therapeutics Stock Down 7.5 %

Shares of NASDAQ HOTH opened at $1.36 on Thursday. The stock’s 50-day simple moving average is $1.05 and its two-hundred day simple moving average is $0.91. Hoth Therapeutics has a twelve month low of $0.58 and a twelve month high of $3.80. The firm has a market capitalization of $9.39 million, a P/E ratio of -1.03 and a beta of 0.75.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). As a group, research analysts anticipate that Hoth Therapeutics will post -1.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.47% of Hoth Therapeutics as of its most recent SEC filing. 7.08% of the stock is currently owned by institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.